TAR-210 results show 90% recurrence-free survival and 90% co

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Vilaseca , Comunidad Autonoma De Cataluna , Spain , United States , Barcelona , Texas , San Antonio , American , Ania Diantonio , Rodriguez Faba , Sabine Brookman , Prnewswire Johnson , Indianj Urol , None Of Janssen Research Development , American Cancer Society , Late Development Oncology , Janssen Research Development , Bladder Cancer Advocacy Network , Janssen Biotech Inc , Drug Administration , Janssen Pharmaceuticals , Astex Pharmaceuticals , Johnson , American Urological Association , European Society For Medical Oncology , Exchange Commission , European Association Of Urology , Oral Presentation Session , Urological Association , Annual Meeting , Bacillus Calmette Gu , European Society , Medical Oncology , European Association , Antoni Vilaseca , Sabine Brookman May , Vice President , Johnson Innovative , Breakthrough Therapy Designation , European Medicines Agency , Soft Tissue Mineralization , Embryo Fetal Toxicity , High Risk Non , Muscle Invasive Bladder , Innovative Medicine , Janssen Research , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Urology Young Academic Urologists , Urol Assoc , Bladder Cancer Advocacy , Accessed April ,